TKT and glioblastoma: The single intratumoral injection of 0.4×106 HSV-TK expressing human bone marrow-derived MSCs followed by five days of systemic GCV administration led to a significant tumor growth inhibition of 86% and prolonged survival in the orthotopic U87 glioblastoma mouse model.